1146 feeds
357 categories
3128 articles (<24 hours)
26 registered users

Use the Mobile version

Follow our Twitter feed

View our Linkpartners


Register | Retrieve


RSS FeedsInnate Pharma highlights FDA-approved LumoxitiŽ at ASH 2019
(WorldNews Health)


8 december 2019 17:50:49

Innate Pharma highlights FDA-approved LumoxitiŽ at ASH 2019
(WorldNews Health)

Sunday, December 8, 2019 - 15:00 Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses maintained in long-term follow-up data Innate Pharma SA (Euronext Paris: IPH - ISIN: FR0010331421; Nasdaq: IPHA) (`Innate` or the `Company`) shared new, long-term data from the pivotal Phase III trial of Lumoxiti (moxetumomab pasudotox-tdfk) today at the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, USA, which expands on the efficacy results and affirms the manageable safety profile of the medicine. The final analysis showed that 36 percent (29/80) of the relapsed or refractory hairy cell...

23 viewsCategory: Science > Medicine
Studies Aim to Improve Outlook for Those Living with Sickle Cell Disease
(WorldNews Health)
ASH Honors Member of Congress and Leaders from the National Institute of Diabetes and Digestive and Kidney Diseases and the National Cancer Institute
(WorldNews Health)
blog comments powered by Disqus

Copyright © 2008 - 2020 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten